The Surgical Prognosis Based Diagnostic Strategy for Eosinophilic Chronic Rhinosinusitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03374124|
Recruitment Status : Recruiting
First Posted : December 15, 2017
Last Update Posted : December 15, 2017
|Condition or disease||Intervention/treatment|
|Sinusitis Nasal Polyps||Diagnostic Test: sinonasal outcome test-22|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||The Surgical Prognosis Based Diagnostic Strategy for Eosinophilic Chronic Rhinosinusitis: A Retrospective Study|
|Actual Study Start Date :||January 2016|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||June 2018|
observe the symptoms and endoscopic appearance
Diagnostic Test: sinonasal outcome test-22
Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
Other Name: Lund-Kennedy endoscopic score
- nasal symptoms [ Time Frame: through study completion, an average of 2 year ]presence of bothersome congestion or rhinorrhea or olfactory loss or headache.(VAS more than 7 points).
- endoscopic appearance indicate the uncontrol of CRS [ Time Frame: through study completion, an average of 2 year ]
The presence of diseased mucosa (nasal polyps, mucopurulent secretions,and/or inflamed mucosa) under endoscopy.
(Lund-kennedy endoscopic score: Polyp≥1 or Oedema≥2 or Discharge≥2; 0-Absence of polyps;1-polyps in middle meatus only;2-polyps beyond middle meatus but not blocking the nose completely;3-polyps completely obstructing the nose.
Oedema: 0-absent; 1-mild; 2-severe.Discharge: 0-no discharge; 1-clear, thin discharge; 2-thick, purulent discharge.)
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03374124
|Contact: Jianbo Shi, email@example.com|
|the first affiliated hospital, Sun Yat-sen University||Recruiting|
|Guangzhou, Guangdong, China, 510080|
|Contact: Fenghong Chen, doctor 02086013560170816 firstname.lastname@example.org|
|Principal Investigator: jianbo Shi, doctor|
|Study Director:||Jianbo Shi, doctor||Ent department, the first affiliated hospital, Sun Yat-sen University|